Faktoren assoziiert mit immuntherapeutischer Sicherheit und Wirksamkeit bei Multiple Sklerose Patienten.
Zusammenfassung der Projektergebnisse
Safety. To the best of our knowledge, our population-based safety study is the largest of its kind examining the relationship between the MS DMDs and infection-related healthcare use. While use of any DMD was not associated with an increased risk of infection-related hospitalizations or rate of physician visits, prescription fills for an anti-infective agent were higher. However, both the route of DMD administration and sex of the person with MS affected these findings. How the differences in infection-related healthcare use identified affect other outcomes in persons with MS warrants further study. Effectiveness. Findings of our effectiveness study suggest that use of the DMDs to treat MS may be more effective in preventing hospitalizations in younger persons (aged <55 years), compared to older individuals (aged ≥55 years). For those aged <55 years, similar trends were observed for both the first and second generation DMDs. In contrast, a more varied and complex picture evolved when the relationship between DMD exposure and physician visits was examined in the older and younger age groups. This might, in part, reflect the different safety-related monitoring strategies required for the different DMDs. Further studies are warranted in order to expand treatment guidelines for an ageing MS population.
Projektbezogene Publikationen (Auswahl)
-
Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population. Frontiers in Immunology, 12.
Ng, Huah Shin; Graf, Jonas; Zhu, Feng; Kingwell, Elaine; Aktas, Orhan; Albrecht, Philipp; Hartung, Hans-Peter; Meuth, Sven G.; Evans, Charity; Fisk, John D.; Marrie, Ruth Ann; Zhao, Yinshan & Tremlett, Helen
